Receptor strategies in pancreatitis

Area of Science:

• Gastroenterology and Hepatology
• Molecular Pharmacology

Background:

• Pancreatic acinar and duct cells possess diverse receptors regulating exocrine secretion and intracellular functions.
• These receptors represent key targets for therapeutic interventions in pancreatitis management.
• Cholecystokinin (CCK) receptor antagonists may alleviate acute pancreatitis by reducing acinar cell metabolic stress.

Purpose of the Study:

• To explore the therapeutic potential of targeting pancreatic receptors for pancreatitis treatment.
• To evaluate the efficacy of CCK receptor antagonists in acute and chronic pancreatitis.
• To assess the role of somatostatin analogs and secretin receptor antagonists in managing pancreatic disorders.

Main Methods:

• Review of studies investigating CCK receptor antagonists in various pancreatitis models.
• Analysis of the effects of somatostatin and its analogs on pancreatic secretion and clinical outcomes.
• Examination of emerging data on secretin receptor antagonists for pancreatic secretion inhibition.

Main Results:

• CCK receptor antagonists demonstrated mitigation of acute pancreatitis severity in several models, though benefits varied by antagonist class.
• Loss of CCK feedback inhibition is implicated in chronic pancreatitis pain, suggesting a role for CCK antagonists.
• Somatostatin analogs effectively treat pancreatic fistulas and pseudocysts and are being evaluated for pain reduction in chronic pancreatitis and severity mitigation in acute pancreatitis.

Conclusions:

• Targeting pancreatic receptors, particularly CCK receptors, offers a promising therapeutic strategy for acute and chronic pancreatitis.
• Somatostatin analogs are valuable for managing complications like fistulas and pseudocysts and may help with pain and severity.
• Secretin receptor antagonists represent a novel approach for selective inhibition of pancreatic secretion, potentially aiding in pancreatitis treatment.